BeOne Medicines Ltd. - Sponsored ADR (NASDAQ:ONC) Receives Average Rating of "Buy" from Analysts

BeOne Medicines Ltd. - Sponsored ADR (NASDAQ:ONC - Get Free Report) has received a consensus rating of "Buy" from the six analysts that are currently covering the stock, Marketbeat Ratings reports. Six investment analysts have rated the stock with a buy recommendation. The average 12-month price objective among brokerages that have issued ratings on the stock in the last year is $320.67.

Several equities research analysts have recently issued reports on the company. TD Securities reaffirmed a "buy" rating and issued a $334.00 target price on shares of BeOne Medicines in a report on Thursday, April 24th. Morgan Stanley lifted their target price on BeOne Medicines from $313.00 to $330.00 and gave the stock an "overweight" rating in a report on Friday, June 27th. Royal Bank Of Canada raised BeOne Medicines from an "outperform" rating to a "moderate buy" rating and set a $311.00 target price on the stock in a report on Friday, June 27th. Wall Street Zen upgraded BeOne Medicines from a "hold" rating to a "buy" rating in a research report on Thursday, May 22nd. Finally, Sanford C. Bernstein set a $259.00 price target on BeOne Medicines in a research report on Thursday, March 13th.

BeOne Medicines Trading Up 1.4%

BeOne Medicines stock traded up $3.48 during trading on Tuesday, reaching $244.47. The company had a trading volume of 265,156 shares, compared to its average volume of 437,808. BeOne Medicines has a 52 week low of $143.00 and a 52 week high of $287.88. The business's 50-day moving average is $247.53. The stock has a market capitalization of $26.79 billion, a price-to-earnings ratio of -65.72 and a beta of 0.28. The company has a debt-to-equity ratio of 0.05, a current ratio of 1.96 and a quick ratio of 1.71.

BeOne Medicines (NASDAQ:ONC - Get Free Report) last posted its quarterly earnings results on Wednesday, May 7th. The company reported $1.22 EPS for the quarter, beating analysts' consensus estimates of ($0.71) by $1.93. The business had revenue of $1.12 billion for the quarter, compared to analysts' expectations of $1.12 billion. BeOne Medicines had a negative return on equity of 7.55% and a negative net margin of 9.40%. On average, analysts predict that BeOne Medicines will post -5.82 earnings per share for the current year.

Insider Buying and Selling at BeOne Medicines

In other BeOne Medicines news, COO Xiaobin Wu sold 1,934 shares of the business's stock in a transaction that occurred on Friday, June 6th. The stock was sold at an average price of $253.15, for a total transaction of $489,592.10. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Xiaodong Wang sold 41,760 shares of the business's stock in a transaction that occurred on Tuesday, May 13th. The shares were sold at an average price of $223.50, for a total value of $9,333,360.00. The disclosure for this sale can be found here. Insiders sold 151,531 shares of company stock worth $37,245,810 over the last 90 days. Company insiders own 6.62% of the company's stock.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in BeOne Medicines stock. Parallel Advisors LLC purchased a new stake in BeOne Medicines Ltd. - Sponsored ADR (NASDAQ:ONC - Free Report) in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 245 shares of the company's stock, valued at approximately $59,000. Hedge funds and other institutional investors own 48.55% of the company's stock.

BeOne Medicines Company Profile

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations.